SOURCE: Large Scale Biology

April 19, 2005 19:30 ET

PerkinElmer and Predictive Diagnostics Announce Discovery of Blood Biomarkers for Alzheimer's Disease

Results of Joint Study Presented at the American Association for Clinical Chemistry Conference

BOSTON, MA & VACAVILLE, CA -- (MARKET WIRE) -- April 19, 2005 -- PerkinElmer Inc. (NYSE: PKI), a leading provider of drug discovery, life science research, and analytical solutions and Predictive Diagnostics, Inc. (PDI), a wholly owned subsidiary of Large Scale Biology Corporation (NASDAQ: LSBC), announced today that they have found a series of biomarkers that appear to differ in persons with Alzheimer's Disease compared to persons without cognitive impairment, using a simple blood test.

The collaborative study, initiated by PerkinElmer and David Bennett, M.D., Director of the Rush Alzheimer's Disease Center, Rush University Medical Center (Chicago, Illinois), is among the first study of its kind to describe a potential diagnostic blood test for Alzheimer's disease, although the results will need replication in a separate study. Mary Lopez, Ph.D., Business Leader for Analytical Proteomics at PerkinElmer presented the results on Thursday, April 14, 2005, at AACC's Oak Ridge Conference in Baltimore, Maryland. The blood analysis was carried out using PerkinElmer's BioXPRESSION™ Biomarker platform and Predictive Diagnostic's proprietary BAMF™ technology to identify patterns of proteins and peptides that distinguish Alzheimer's disease patients from those without clinical signs. The serum samples used in the study were donated by the Rush University Medical Center.

PerkinElmer's state-of-the-art BioXPRESSION™ Biomarker discovery and screening platform includes the novel prOTOF 2000™ MALDI mass spectrometer, ProXPRESSION™ carrier protein-based blood biomarker enrichment kits and PDI's BAMF™ technology.

"This study demonstrates the power of our comprehensive suite of tools and technologies for biomarker discovery and analysis," said Peter Coggins, Ph.D., president of PerkinElmer Life and Analytical Sciences. "We believe the detection of early disease-related biomarkers is crucial to facilitate the development of diagnostics and drug therapies."

In numerous collaborative studies, Predictive Diagnostics has demonstrated the capability of its BAMF™ technology to accurately diagnose cancers such as breast, lung, pancreatic and prostate, as well as multiple sclerosis. Predictive Diagnostics believes its diagnostic tests will provide better patient outcome through early detection of cancer and other serious diseases and significantly reduce the cost of healthcare associated with treatment of such diseases.

Further information about Predictive Diagnostics, Inc. can be found on the company's website (www.predictivediagnostics.com).

About PerkinElmer

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Industrial Sciences markets to improve the quality of life. The Company reported revenues of $1.7 billion in 2004, has 10,000 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

About Large Scale Biology Corporation

Large Scale Biology Corporation is a biotechnology company developing and biomanufacturing biotherapeutics, diagnostic tests, vaccines and industrial proteins for important life science industry markets. Corporate headquarters, molecular biology and product design laboratories, and Predictive Diagnostics, Inc., are located in Vacaville, California, and the Company's bioprocess development and commercial-scale biomanufacturing facilities are located in Owensboro, Kentucky. In addition to its class-leading internal capabilities, LSBC relies on a network of industry, government and academic collaborators throughout the US and Europe to achieve rapid, commercially relevant product discovery, optimization and manufacturing. For more information about Large Scale Biology Corporation, visit the Company's website at www.lsbc.com.

LSBC® and BAMF™ are trademarks of Large Scale Biology Corporation.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that relate to prospective events or developments, including, without limitation, all projections of future financial results, are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important risk factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including, without limitation, economic and geopolitical forces that may limit any continued or expected economic or end market strengthening or recoveries, risks related to our failure to introduce new products in a timely manner, the impact of our debt on our cash flow and investment opportunities, our ability to comply with financial covenants contained in our credit agreements and debt instruments, cyclical downturns continuing to affect several of the industries into which we sell our products, our ability to adjust our operations to address unexpected changes, our ability to execute acquisitions and license technologies and successfully integrate acquired businesses and licensed technologies into our existing business, the loss of any of our licenses that may require us to stop selling products or lose competitive advantage, competition, regulatory compliance, regulatory changes, our failure to obtain and enforce intellectual property protection, our defense of third party claims of patent infringement and our ability to realize the full value of our intangible assets, as well as other factors, which we describe under the caption "Forward-Looking Information and Factors Affecting Future Performance" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q, each on file with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

This release contains forward-looking statements about applications of LSBC and Predictive Diagnostics' technologies and potential market opportunities for our diagnostic tests. These forward-looking statements involve risks, uncertainties and situations that may cause our actual results to differ materially from those implied by these statements, including our ability to commercialize applications of our technologies, the ability of our collaborators to generate demand for the diagnostic applications, the effectiveness of our and our collaborators' technologies to produce specific diagnostics or provide services and/or in a cost-effective manner, any difficulties or delays in obtaining regulatory approval to test and market such diagnostics or services, and the requirement of substantial funding for us to preserve our technology base and diagnostic applications. We cannot guarantee future results. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this release. For a further list and description of such risks and uncertainties see the reports filed by Large Scale Biology Corporation with the Securities and Exchange Commission, including our reports on Forms 10-K and 10-Q. Except as required by law, we do not undertake to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact Information


  • For further information:

    Dan Sutherby
    PerkinElmer, Inc.
    (781) 431-4306

    Steve Marchant
    Brodeur Worldwide
    (617) 587-2864

    Guy della Cioppa, Ph.D.
    Predictive Diagnostics, Inc.
    707-469-2358